As your body adjusts to these powerful treatments, it can lose vital fluids, electrolytes, and nutrients through nausea, vomiting, and digestive upset
Articles were excluded if they non-human trials or were secondary research methods including meta-analyses, systematic or non-systematic reviews, scoping reviews, narrative review and literature reviews
This effect stems from weight loss itself combined with possible direct vascular effects
GLP-1 emerged as a target for T2D treatment due to its unique mechanism of action
Decreases over time varied by income groups, which may indicate different treatment patterns by income groups since 2020
This makes it the first "triple agonist" to reach human clinical trials